Loading…
← CockpitCompetitor Analysis › 9637.HK Alebund Pharmaceuticals (Jiangsu) Limited Class HOpen in the cockpit ↗

Alebund Pharmaceuticals (Jiangsu) Limited Class H9637.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Mkt cap
$595M
US dollars, full cap
Free float
46%
of shares outstanding
$/day
$1.56M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-89.4 pp
WACC 5.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · HKDHK$19.95
1D0.0%
1W-5.0%
1M+18.3%
3M-39.9%
6Mn/a
YTDn/a
1Yn/a
ATR %8.3%
52w lowhigh57.4% off high

What Alebund Pharmaceuticals (Jiangsu) does

Employees: 162

Alebund Pharmaceuticals (Jiangsu) at a glance

Size Alebund Pharmaceuticals (Jiangsu) (9637.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $595M, the 701st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$19.95 on 18 Nov 2026.

Growth Revenue grew 673.9% over the last twelve months (peer median +14.5%); the operating margin is -494.9% (peer median -28.7%).

Valuation It trades at 26.8× enterprise value to sales against a peer median of 3.4× (4th most expensive of 16).

Capital Return on invested capital runs 89.4 points below its cost of capital (5.5% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Alebund Pharmaceuticals (Jiangsu) financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
RevenueHK$139MHK$33.1MHK$7.07MHK$0
Revenue growth—+368%——
Gross profitHK$69.5M-HK$29.8M-HK$9.87M-HK$12.8M
EBITDA-HK$636M-HK$653M-HK$323M-HK$399M
Net income-HK$778M-HK$813M-HK$353M-HK$403M
Free cash flow-HK$479M-HK$443M-HK$537M-HK$552M
Capital expenditureHK$80.7MHK$110MHK$257MHK$222M
Total debtn/aHK$612MHK$510MHK$203M

Quarterly statements and history in the cockpit →

Alebund Pharmaceuticals (Jiangsu) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Fundamentals: revenue growth against valuation

0%+20,000%+40,000%+60,000%+80,000%0×1,000×688639SRZNFDMT16729637.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alebund Pharmaceuticals (Jiangsu) is the large dot.

Alebund Pharmaceuticals (Jiangsu) competitors and peer comparison

How Alebund Pharmaceuticals (Jiangsu) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alebund Pharmaceuticals (Jiangsu) against its 20 peers (data as of 18 Nov 2026)
Measure9637.HKPeer medianRank in peer set
1-month return+18.3%-15.3%4th highest of 21
Distance from 52-week high-57.4%-44.8%7th lowest of 21
Revenue growth (TTM)+673.9%+14.5%3rd highest of 17
Operating margin-494.9%-28.7%3rd lowest of 17
EV / Sales26.8×3.4×4th most expensive of 16
ROIC minus cost of capital-89.4 pp-9.3 pp3rd lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%3.2×n/an/a
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%2.3×14.3%+15.4%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a

Questions

Which companies are Alebund Pharmaceuticals (Jiangsu)'s closest peers?
The cockpit's peer set: Anhui Huaheng Biotechnology (688639.SS), Surrozen (SRZN), Design Therapeutics (DSGN), 4D Molecular Therapeutics (FDMT), Ascletis Pharma (1672.HK), Genfit (GNFT.PA), Getein Biotech (603387.SS), Boji Medical Technology (300404.SZ).
Is Alebund Pharmaceuticals (Jiangsu) expensive compared with its peers?
On ev / sales it trades at 26.8× against a peer median of 3.4×, 4th most expensive of 16 in its peer set.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.